Intuitive Surgical to report Q2 earnings July 16 with $2.81B sales estimate

Key Takeaways:

Consensus sales estimate of $2.81 billion implies 15% year-over-year growth
EPS estimate of $2.48, with the Most Accurate Estimate at $2.55 per share
Stock down 27.4% year to date despite 23% revenue growth in Q1

Intuitive Surgical is set to report second-quarter results on July 16, with analysts projecting revenue of $2.81 billion, up 15% from a year earlier, and earnings per share of $2.48, a 13.2% increase.

"The da Vinci 5 upgrade cycle remains the biggest growth catalyst over the next several quarters, with customer adoption exceeding expectations," the company said in its Q1 outlook, noting nearly 1,500 da Vinci 5 systems installed and approximately 13,000 surgeons already using the platform.

The company delivered a 20.19% earnings surprise in the last reported quarter and has beaten estimates in each of the trailing four quarters, averaging 16.82%. The Most Accurate Estimate for Q2 stands at $2.55, giving a positive Earnings ESP of 2.78%, according to Zacks data. Intuitive Surgical carries a Zacks Rank #2 (Buy).

Despite robust financial performance — 23% revenue growth and a 36% increase in adjusted earnings during the first quarter of 2026 — the stock has declined 27.4% year to date, underperforming the S&P 500's 9.5% gain and the broader medical-instruments industry's 14.2% decline. The forward P/E multiple has compressed from 96.05 times at the start of 2025 to 37.12 times currently.

Margin Pressure Weighs on Sentiment

The biggest investor concern centers on the da Vinci 5 rollout, which carries lower margins than the mature Xi platform due to higher manufacturing, service and support costs. Management expects elevated trade-in activity as hospitals replace older systems, creating an additional drag on profitability. Tariffs, higher freight expenses and rising semiconductor memory costs are expected to increase input costs through the remainder of the year.

The company guided full-year da Vinci procedure growth of 13.5% to 15.5% and a non-GAAP gross profit margin between 67.5% and 68.5% of revenue. Other income is expected to total between $315 million and $335 million, reflecting lower average cash balances after share repurchase activity in Q1.

Recurring Revenue Provides a Buffer

Recurring revenue accounted for 86% of total sales in Q1, highlighting the resilience of the business model. U.S. da Vinci utilization increased 4% during the quarter, while da Vinci 5 utilization runs approximately 11% higher than the legacy Xi platform. The company is also investing in AI-enabled capabilities through its digital ecosystem, leveraging surgical video, robotic data and force-feedback information to develop anatomy identification and decision-support tools.

Competition is intensifying as Stryker, Zimmer Biomet, Globus Medical and Stereotaxis expand their robotic surgery offerings. Stryker's Mako system, Zimmer Biomet's ROSA platform and Globus Medical's ExcelsiusGPS all target segments of the surgical robotics market that Intuitive Surgical has long dominated.

The Q2 report will test whether margin headwinds from the da Vinci 5 transition are easing. A beat on both revenue and EPS, combined with maintained or raised procedure growth guidance, could reverse some of the stock's year-to-date decline. Investors will also watch for updates on international adoption, particularly in Japan and China, and any commentary on the impact of GLP-1 drugs on bariatric procedure volumes.

This article is for informational purposes only and does not constitute investment advice.